Redeye provides an initial take following the release of Corline’s Q3 2025 report. Sales came in lower than expected; however, we see no cause for concern and expect the Kardium-driven ramp-up to become more evident in upcoming reports. We will publish a research update, where some minor estimate revisions may be made, but we do not anticipate any material impact on our valuation.
LÄS MER
